Rhythm Pharmaceuticals Inc. (RYTM) 今日盘前股价大涨5.58%,引发市场关注。
消息面上,公司公布了在研药物Rm-718的二期临床试验初步数据,该药物在治疗获得性下丘脑肥胖方面展现出积极的疗效信号,且耐受性良好,常见不良反应为注射部位反应、恶心及呕吐,均属可控范围。
这一积极进展为相关治疗领域带来了突破希望,提振了投资者对公司前景的信心。
Rhythm Pharmaceuticals Inc. (RYTM) 今日盘前股价大涨5.58%,引发市场关注。
消息面上,公司公布了在研药物Rm-718的二期临床试验初步数据,该药物在治疗获得性下丘脑肥胖方面展现出积极的疗效信号,且耐受性良好,常见不良反应为注射部位反应、恶心及呕吐,均属可控范围。
这一积极进展为相关治疗领域带来了突破希望,提振了投资者对公司前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.